Pressure BioSciences (PBIO) Reports a Q3 Loss, Comments on Outlook
More News related to PBIO
- UNTHSC Scientist Using Pressure BioSciences' (PBIO) Pressure Cycling Technology Increased DNA Yields From Challenging Samples
- Significant Improvements in DNA Yield From Challenging Forensic Samples Reported With Pressure Cycling Technology (PCT)
- Pressure BioSciences (PBIO) and Protein Forest Enter Collaboration
- Pressure BioSciences, Inc. and Protein Forest, Inc. Announce Collaborative Co-Marketing/Selling and R&D Agreement
- Pressure BioSciences, Inc. Releases Two Novel, PCT-Dependent Sample Preparation Kits for the Proteomic Research Market
More News related to Earnings
- UMH Properties (UMH) Posts Q3 FFO of $0.12, Better Y/Y; Revs Beat Estimates
- Carrizo Oil & Gas (CRZO) Posts Q3 adj.-EPS of $0.37, Tops Views
- While Q3 Profits Slide at DISH Network (DISH), Investors Treated With Subscribers Gains and Special Dividend
- Sanders Morris Harris Group (SMHG) Misses Q3 EPS by 2c
- Connecticut Water Service (CTWS) Posts Q3 EPS of 83c, Tops Views
Pressure BioSciences, Inc. (Nasdaq: PBIO) reports a Q3 loss of $0.50 compared to a loss of $0.53 for the same period last year. Total revenue for the third quarter of 2008 was $265,662 compared to $138,052 for the comparable period in the prior year.
"Compelling data have recently been presented to the US scientific community showing a significant improvement in the speed and quality of protein digestion when using PCT prior to MS analysis. Our French and Japanese distributors have informed us that they intend to target their own MS market in 2009, and have indicated that they have seen a growing interest in this important application area. Last week, our Chinese distributor reported that a major national scientific academy in China had generated similar, exciting, PCT-enhanced protein digestion results...We have therefore concluded that the application of PCT-enhanced protein digestion for the mass spectrometry market will be our primary development and sales focus during 2009. We are currently determining the extent of the effect of this realignment on our current operations and cost structure. These activities are dependent upon the successful completion of our ongoing capital raising efforts."
Pressure BioSciences, Inc. is a life sciences company focused on the development and commercialization of a platform technology called pressure cycling technology (PCT). [SM]
Related Categories
EarningsGuidance
Stocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
